First-in-human study of a novel radiolabeled fibroblast activating protein (FAP)-targeted peptide 68Ga-FAP-3BP-3940 for PET/CT imaging in patients with solid tumors

被引：0
|
作者：
Jakobsson, Vivianne [1 ]
Zhang, Jingjing [2 ]
Greifenstein, Lukas [1 ]
Huang, Juncheng
Chen, Xiaoyuan [3 ]
Baum, Richard P. [1 ]
机构：
[1] Curanosticum Wiesbaden Frankfurt, Frankfurt, Germany
[2] Natl Univ Singapore NUS, Singapore, Singapore
[3] NUS, Singapore, Singapore
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P1615
引用
收藏
页数：2
相关论文
共 17 条
  • [11] A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
    Melero, Ignacio
    Tanos, Tamara
    Bustamante, Mariana
    Sanmamed, Miguel F.
    Calvo, Emiliano
    Moreno, Irene
    Moreno, Victor
    Hernandez, Tatiana
    Garcia, Maria Martinez
    Rodriguez-Vida, Alejo
    Tabernero, Josep
    Azaro, Analia
    Ponz-Sarvise, Mariano
    Spanggaard, Iben
    Rohrberg, Kristoffer
    Guarin, Ernesto
    Nuesch, Eveline
    Davydov, Iakov I.
    Ooi, Chiahuey
    Duarte, Jose
    Chesne, Evelyne
    McIntyre, Christine
    Ceppi, Maurizio
    Canamero, Marta
    Krieter, Oliver
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (695)
  • [12] Preclinical Evaluation and First-in-Human Study of [68Ga]Ga-αvβ6-2: A Novel Dimeric Integrin αvβ6-Targeted PET Probe for Pancreatic Cancer Imaging
    Pang, Xiao
    Zhao, Yan
    Chen, Xiaolin
    Zhao, Xinming
    Wang, Mengjiao
    Chen, Xiaoshan
    Yuan, Huiqing
    Sun, Yuhan
    Han, Jingya
    MOLECULAR PHARMACEUTICS, 2025,
  • [13] First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with 68Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting
    Baum, Richard P.
    Kulkarni, Harshad R.
    Mueller, Dirk
    Satz, Stanley
    Danthi, Narasimhan
    Kim, Young-Seung
    Brechbiel, Martin W.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2015, 30 (04) : 152 - 159
  • [14] First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability
    Clausen, Malene Martini
    Carlsen, Esben Andreas
    Christensen, Camilla
    Madsen, Jacob
    Brandt-Larsen, Malene
    Klausen, Thomas Levin
    Holm, Soren
    Loft, Annika
    Berthelsen, Anne Kiil
    Kroman, Niels
    Knigge, Ulrich
    Kjaer, Andreas
    DIAGNOSTICS, 2022, 12 (04)
  • [15] Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
    Kelly K. Curtis
    John Sarantopoulos
    Donald W. Northfelt
    Glen J. Weiss
    Kerry M. Barnhart
    John K. Whisnant
    Carola Leuschner
    Hector Alila
    Mitesh J. Borad
    Ramesh K. Ramanathan
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 931 - 941
  • [16] Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
    Curtis, Kelly K.
    Sarantopoulos, John
    Northfelt, Donald W.
    Weiss, Glen J.
    Barnhart, Kerry M.
    Whisnant, John K.
    Leuschner, Carola
    Alila, Hector
    Borad, Mitesh J.
    Ramanathan, Ramesh K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 931 - 941
  • [17] First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
    Melero, I.
    Sanmamed, M. F.
    Calvo, E.
    Moreno, I.
    Moreno, V.
    Hernandez Guerrero, T. C.
    Martinez-Garcia, M.
    Rodriguez-Vida, A.
    Tabernero, J.
    Azaro Pedrazzoli, A. B.
    Spanggaard, I.
    Rohrberg, K. S.
    Guarin, E.
    Nueesch, E.
    Chesne, E.
    Ceppi, M.
    Sweere, U.
    McIntyre, C.
    Lichtenegger, F. S.
    Krieter, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S707 - S707
12